Trials / Not Yet Recruiting
Not Yet RecruitingNCT06010667
A Prospective, Randomized Controlled Study of Cyclophosphamide, Bevacizumab With or Without Envafolimab in Recurrent Epithelial Ovarian Cancer (EOC), Fallopian Tube Cancer, and Primary Peritoneal Cancer
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 60 (estimated)
- Sponsor
- Hebei Medical University Fourth Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to evaluate the efficacy and safety of cyclophosphamide and bevacizumab in combination with Envafolimab in the treatment of recurrent epithelial ovarian cancer (EOC), fallopian tube cancer, and primary peritoneal cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Envafolimab | With or without Envafolimab |
Timeline
- Start date
- 2023-09-01
- Primary completion
- 2024-08-01
- Completion
- 2026-08-01
- First posted
- 2023-08-24
- Last updated
- 2023-08-24
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06010667. Inclusion in this directory is not an endorsement.